Malaria is caused by parasites that are transmitted to people through the bites of infected female mosquitoes. P. falciparum is the most deadly malaria parasite and the most prevalent in Africa, where malaria cases and deaths are heavily concentrated. The first symptoms of malaria – fever, headache, chills and vomiting – usually appear between 10 and 15 days after the mosquito bite. Without prompt treatment, P. falciparum malaria can progress to severe illness and death.
WHO recommends a multi-pronged strategy to prevent, control and eliminate malaria. Key interventions include: the use of insecticide-treated mosquito nets and indoor residual spraying, diagnostic testing, and treatment of confirmed cases with effective anti-malarial medicines. In recent years, these measures have dramatically lowered the malaria burden in many settings. Malaria transmission continues in many countries around the world however, and causes hundreds of thousands of deaths each year.
For more information about Malaria, please visit about Malaria.
|Global disability-adjusted life years (DALYs)||55,111,091||2012|
|Global estimated number of deaths||438 000 [236 000-635 000]||2015|
|Global estimated number of cases||214 000 000 [149 000 000-303 000 000]||2015|
|Total number of under-five deaths from malaria||564,000||2010|
|Global malaria incidence (per 100 000 population)||4,082||2010|
|Incidence in African Region*||20,912|
|Incidence in Americas Region||193|
|Incidence in Eastern Mediterranean Region||2,490|
|Incidence South-East Asia Region||1,772|
|Incidence in Western Pacific Region||103|
|Unmet need for family planning (%)||12.00||2012|
|Births attended by skilled health personnel (%)||74.00||2014|
|Maternal mortality ratio (per 100 000 live births) - Interagency estimates||216||2015|
|Global number of reported cases||215,636||2013|
|Global estimated number of prevalent tuberculosis cases||13 000 000 [11 000 000-14 000 000]||2014|
|Global estimated number of incident tuberculosis cases||9 600 000 [9 100 000-10 000 000]||2014|
|TB patients with known HIV status (%)||51.00||2014|
|Confirmed cases of RR-/MDR-TB||122,789||2014|
|Confirmed cases of MDR-TB||85,085||2012|
|Tuberculosis treatment success under DOTS (%)||85.00||2006|
|Treatment success rate for patients treated for MDR-TB (%)||50.00||2012|
|Treatment success rate: XDR-TB cases (%)||26.00||2012|
|Estimated number of people (all ages) living with HIV||35 000 000 [33 200 000 - 37 200 000]||2013|
|Estimated antiretroviral therapy coverage among people living with HIV (%) in low-income countries||38||2013|
|Status of endemicity for blinding trachoma||50||2012|
|Status of yaws endemicity||13||2013|
|Status of endemicity of cutaneous leishmaniasis||82||2013|
|Status of endemicity of visceral leishmaniasis||74||2013|
|Total number of reported cases||129,067||2013|
*These Regions correspond to the WHO Regions
The Global Health Observatory provides aggregate data for meningitis only, which means that the numbers provided in this section refer to bacterial meningitis, meningococcal meningitis and meningitis due to unspecified causes.
According to analyses by Policy Cures' G-FINDER survey, were spent in on R&D for new products for Malaria. This constituted 0 %% of the 0M that were spent on global neglected disease R&D for new products in total in .
There are no data available from Policy Cures' G-FINDER survey about Malaria.
Note: The data from Policy Cures' G-FINDER survey are limited to funding for product development. Furthermore, the data are collected using specific definitions for diseases and limitations in terms of products to ensure that the data concern diseases that A) disproportionately affect people in developing countries, B) for which there is a need for new products, and C) for which there is market failure in developing these new products. For Malaria, this means that data on funding for the conduct of basic research, and for the development of drugs, preventive vaccines, diagnostics and vector control products is included. Importantly, the funding reflected here includes the total amount allocated for different malaria strains, including <i>P. falciparium and P. vivax</i> and other and/or unspecified malaria strains. Care should be taken when interpreting this R&D funding data in conjunction with other data on this page because of potential differences in scope and other confounding factors. See the WHO Global Observatory on Health R&D User Guide for more details.
This section describes what is known about health technologies (such as drugs, vaccines or diagnostics) that are in the R&D pipeline for Malaria. For this health issue there is/are 1 data source(s) that has/have provided R&D pipeline data to the WHO Global Observatory on Health R&D:
Note on all R&D pipeline analyses: Data on products in the pipeline are shown for three types of products (drugs, vaccines and diagnostics) and only when a data source has collected data on that product type. Clinical development stage data are much more reliable than preclinical development stage data; it is likely that more products are in preclinical development than is publicly known. Presented preclinical data exclude discovery stage products. For diagnostics only the total number of products in development is reported because the distinction between various stages of development is less clear for this group of products. Percentages for types of developers and product types (for drugs) do not add to 100% because categories can overlap. See the User Guide of the Global Observatory on Health R&D for more information about the R&D pipeline data presented here, for descriptions of the data sources that have provided these data (and their limitations) and for an overview of all classifications in use by the WHO Global Observatory on Health R&D, such as for R&D stage.
There are no registered clinical trials for in the ICTRP database
About the WHO ICTRP: the WHO ICTRP is the most inclusive global data source on clinical trials; it combines data from 16 clinical trial registries around the world.
For the WHO ICTRP database, some of the data are classified using categories that are not mutually exclusive. For example, a trial can recruit in multiple countries and regions. Therefore, such data cannot be represented as a stacked bar-chart as above. To be able to display the WHO ICTRP data disaggregated by the UN region in which the trials are recruiting, here below we show the data from the WHO ICTRP as a line graph.
Note: The graphs include both trials that are recruiting participants and trials that are not. More information on the search methodology and classifications used to develop these graphs can be found in the User Guide of the WHO Global Observatory on Health R&D. These data were last updated on 29 April 2016.
In 1900 there were 0 publications on PubMed indexed as being about Malaria. The figure below displays how the number of publications for Malaria developed over time.
There are no data available for medical publication about Malaria.